vimseltinib   Click here for help

GtoPdb Ligand ID: 11190

Synonyms: compound 20 [PMID: 35961460] | DCC-3014 | DCC3014 | example 10 [WO2014145025A2]
PDB Ligand
Compound class: Synthetic organic
Comment: The chemical structure submitted to the WHO for the INN vimseltinib is identical to that of the investigational, oral CSF1R inhibitor DCC-3014, via a PubChem structure match. The compound is claimed as example 10 in Deciphera Pharmaceuticals' patent WO2014145025A2, in which KIT proto-oncogene inhibitory activity is also noted [1]. Name to structure was formally disclosed in Caldwell et al. (2022) [2]. Vimseltinib's selectivity is determined by its interactions within the switch control region of the CSF1R that regulates kinase conformational activation.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 99.75
Molecular weight 431.21
XLogP 3.58
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC(Nc1ncc(c(=O)n1C)c1ccc(c(n1)C)Oc1ccnc(c1)c1cnn(c1)C)C
Isomeric SMILES CC(Nc1ncc(c(=O)n1C)c1ccc(c(n1)C)Oc1ccnc(c1)c1cnn(c1)C)C
InChI InChI=1S/C23H25N7O2/c1-14(2)27-23-25-12-18(22(31)30(23)5)19-6-7-21(15(3)28-19)32-17-8-9-24-20(10-17)16-11-26-29(4)13-16/h6-14H,1-5H3,(H,25,27)
InChI Key TVGAHWWPABTBCX-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
DCC-3014 has progressed to clinical trial, principally to ascertain potential efficacy in the treatment of tenosynovial giant cell tumour (TGCT; a benign disease that's driven by CSF1R-dependent macrophages) [3].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04242238 Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas Phase 1 Interventional Memorial Sloan Kettering Cancer Center
NCT03069469 Study of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor Phase 1/Phase 2 Interventional Deciphera Pharmaceuticals LLC
NCT05059262 Study of Vimseltinib for Tenosynovial Giant Cell Tumor Phase 3 Interventional Deciphera Pharmaceuticals LLC